Clinicopathological Profile, Treatment Patterns and Documented Clinical Outcomes of Women with Breast Cancer at Shendi Hospital, Sudan: A Retrospective, Single-Center, Hospital-Based Cross-Sectional Study.
8 affiliations
- 1Department of Medical Laboratory Technology, College of Applied Medical Sciences, Northern Border University, Arar, Saudi Arabia.
- 2Department of Clinical Laboratory Science, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia.
- 3Department of Pathology, College of Medicine, King Khalid University, Abha, Saudi Arabia.
- 4Department of Community Health, Faculty of Applied Medical Sciences, Northern Border University, Arar, Saudi Arabia.
- 5Center for Health Research, Northern Border University, Arar, Saudi Arabia.
- 6Department of Hematology, Faculty of Medical Laboratory Sciences, Al-Neelain University, Khartoum, Sudan.
- 7Faculty of Medical Laboratory Sciences, University of Gadarif, Gadarif, Sudan.
- 8Department of Medical Laboratory Sciences, College of Health Sciences, Gulf Medical University, Ajman, United Arab Emirates.
Abstract
Breast cancer is the most common cancer in Sudan, yet hospital-based data from outside Khartoum are scarce. We described the clinicopathological profile, treatment and documented outcomes of women with breast cancer at Shendi Hospital and explored factors associated with recurrence, distant metastasis and global well-being. In this retrospective, single-center, cross-sectional review, we abstracted records of 100 women with histologically confirmed invasive breast cancer managed in 2021-2025. Distant metastasis was defined as documented extranodal disease, and global well-being as a single good/fair/poor rating recorded in clinical notes. Associations were examined with exact tests and three pre-specified Firth penalized logistic regression models (four covariates each) with bootstrap validation; all inferential analyses were exploratory. Median age was 50 years (IQR 44-55). Stage III/IV disease was recorded in 72%, tumors >2 cm in 97% and nodal involvement in 73%. Receptor status was undocumented in 69%; all 31 documented results were hormone-receptor-negative (18 triple-negative, 13 HER2-positive), yet 16 of these women had recorded hormonal therapy. Mastectomy was performed in 65%; chemotherapy, radiotherapy and hormonal therapy were recorded in 99%, 48% and 45%. Recurrence was documented in 19/98 women (19%) and extranodal metastasis in 30/93 (32%); no deaths were recorded and follow-up duration was unknown. Tumors >5 cm were associated with recurrence (adjusted odds ratio 3.81, 95% CI 1.28-11.61), and extranodal metastasis with a fair well-being rating (5.64, 2.01-17.20); nodal status, economic status and age were not associated with any outcome after adjustment. Recorded treatment co-occurred with recurrence, but treatment timing was undocumented, precluding causal interpretation. Women at this center presented with advanced disease, and receptor documentation was largely absent and internally inconsistent. These exploratory associations need confirmation in prospective studies with complete receptor testing, dated treatment records and active follow-up.
Related
- Multidimensional patterns of malocclusion in treatment-seeking Turkish orthodontic patients : A retrospective cross-sectional study
- Cardiovascular risk profile and treatment patterns in patients with type 2 diabetes in specialized cardiology outpatient care in Colombia : A retrospective cross-sectional study
- Real-World Clinicopathological Characteristics, Metastatic Distribution, and Treatment Patterns of Triple-Negative Breast Cancer: A Single-Institution Experience from Nigeria
- Serum Thyrotropin Levels Across Older Age Groups in Geriatric Outpatients Without Documented or Clinically Evident Thyroid Disease: A Retrospective Cross-Sectional Study
- Clinicopathological diagnostic concordance among autopsied adults living with HIV in the Brazilian Amazon: A retrospective cross-sectional study
BibTeX
@article{ali2026clinicopathological,
title = {{Clinicopathological Profile, Treatment Patterns and Documented Clinical Outcomes of Women with Breast Cancer at Shendi Hospital, Sudan: A Retrospective, Single-Center, Hospital-Based Cross-Sectional Study.}},
author = {Elryah I Ali and Saadalnour Abusail Mustafa and Husham O Elzein and Mohamed O Andarawi and Mohammed Suleiman Zaroog and Awad-Elkareem Abass and Gamila Ali Attaelmanan and Fatima Mohamed Osman Yasin and Ayman Hussein Alfeel and Marwan Ismail},
journal = {Breast cancer (Dove Medical Press)},
year = {2026},
month = oct,
doi = {10.2147/bctt.s650507},
url = {https://europepmc.org/article/MED/42953391},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Clinicopathological Profile, Treatment Patterns and Documented Clinical Outcomes of Women with Breast Cancer at Shendi Hospital, Sudan: A Retrospective, Single-Center, Hospital-Based Cross-Sectional Study.
AU - Elryah I Ali
AU - Saadalnour Abusail Mustafa
AU - Husham O Elzein
AU - Mohamed O Andarawi
AU - Mohammed Suleiman Zaroog
AU - Awad-Elkareem Abass
AU - Gamila Ali Attaelmanan
AU - Fatima Mohamed Osman Yasin
AU - Ayman Hussein Alfeel
AU - Marwan Ismail
PY - 2026
DA - 2026/10/24
JO - Breast cancer (Dove Medical Press)
DO - 10.2147/bctt.s650507
UR - https://europepmc.org/article/MED/42953391
AB - Breast cancer is the most common cancer in Sudan, yet hospital-based data from outside Khartoum are scarce. We described the clinicopathological profile, treatment and documented outcomes of women with breast cancer at Shendi Hospital and explored factors associated with recurrence, distant metastasis and global well-being. In this retrospective, single-center, cross-sectional review, we abstracted records of 100 women with histologically confirmed invasive breast cancer managed in 2021-2025. Distant metastasis was defined as documented extranodal disease, and global well-being as a single good/fair/poor rating recorded in clinical notes. Associations were examined with exact tests and three pre-specified Firth penalized logistic regression models (four covariates each) with bootstrap validation; all inferential analyses were exploratory. Median age was 50 years (IQR 44-55). Stage III/IV disease was recorded in 72%, tumors >2 cm in 97% and nodal involvement in 73%. Receptor status was undocumented in 69%; all 31 documented results were hormone-receptor-negative (18 triple-negative, 13 HER2-positive), yet 16 of these women had recorded hormonal therapy. Mastectomy was performed in 65%; chemotherapy, radiotherapy and hormonal therapy were recorded in 99%, 48% and 45%. Recurrence was documented in 19/98 women (19%) and extranodal metastasis in 30/93 (32%); no deaths were recorded and follow-up duration was unknown. Tumors >5 cm were associated with recurrence (adjusted odds ratio 3.81, 95% CI 1.28-11.61), and extranodal metastasis with a fair well-being rating (5.64, 2.01-17.20); nodal status, economic status and age were not associated with any outcome after adjustment. Recorded treatment co-occurred with recurrence, but treatment timing was undocumented, precluding causal interpretation. Women at this center presented with advanced disease, and receptor documentation was largely absent and internally inconsistent. These exploratory associations need confirmation in prospective studies with complete receptor testing, dated treatment records and active follow-up.
SN - 1179-1314
ER -